Drug news
NICE now recommends Perjeta (pertuzumab) to treat HER 2 positive early stage breast cancer. - Roche
The National Institute for Health and Clinical Excellence (NICE) has in draft guidance changed its negative recommendation on the routine use of Perjeta (pertuzumab) from Roche, to treat breast cancer. It now recommends Perjeta as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence, when used in combination with trastuzumab. A confidential price discount from Roche now makes the drug cost effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.